Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial — Miguel A. Villalona‐Calero (2020) | RDL Network
Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial
Article 2020 en
Authors
MV
Miguel A. Villalona‐Calero
EV
Everett E. Vokes
MC
Marzia Capelletti
Abstract
1 min read
Erlotinib is clinically effective in patients with non–small-cell lung cancer (NSCLC) who have adenocarcinoma, are never or limited former smokers, or have EGFR mutant tumors. We investigated the efficacy of erlotinib alone or in combination with chemotherapy in patients with these characteristics.
P. Kosmidis, Haralabos P. Kalofonos, K. Syrigos, D. Skarlos, George Fountzilas, C. Nicolaides, D. Bafaloukos, E. Samantas, C. Bakogiannis, Meletios A Dimopoulos
P. Kosmidis, Eleni Timotheadou, Αngelos Koutras, George Pentheroudakis, C. Christodoulou, Meletios A Dimopoulos, D. Bafaloukos, E. Samantas, Dimitrios Pectasides, K. Syrigos
Discussion(0)
No comments yet. Be the first to comment.